共 50 条
- [31] Intraoperative Radiation Therapy for Relapsed or Refractory High-Risk Neuroblastoma: A 27-Year ExperiencePRACTICAL RADIATION ONCOLOGY, 2024, 14 (03) : e226 - e232Conte, BriannaCasey, Dana L.Tringale, Kathryn R.Honeyman, JoshuaNarayan, Nicole J. C.Laquaglia, Michael P.Gerstle, Justin TedModak, ShakeelKushner, Brian H.Kramer, KimWolden, Suzanne L.
- [32] Retrospective analysis of relapsed abdominal high-risk neuroblastomaJOURNAL OF PEDIATRIC SURGERY, 2018, 53 (03) : 558 - 566Duebbers, MartinSimon, ThorstenBerthold, FrankFischer, JaninaVolland, RuthHero, BarbaraCernaianu, Grigore
- [33] Naxitamab Treatment of Refractory/Relapsed High-Risk Neuroblastoma (R/R HR NB); Subgroup Analysis of Updated Interim Efficacy and Safety Data for The Registrational Phase II TrialPEDIATRIC BLOOD & CANCER, 2021, 68 : S85 - S85Mora, J.Bear, M.Chan, G. Chi-FungMorgenstern, D.Nysom, K.Tornoe, K.Losic, N.Kushner, B.
- [34] Treatment and Outcomes of Patients With Relapsed, High-Risk Neuroblastoma: Results of German TrialsPEDIATRIC BLOOD & CANCER, 2011, 56 (04) : 578 - 583Simon, ThorstenBerthold, FrankBorkhardt, ArndtKremens, BernhardDe Carolis, BorisHero, Barbara
- [35] DFMO Maintains Remission in Relapsed/Refractory High Risk NeuroblastomaPEDIATRIC BLOOD & CANCER, 2017, 64 : S46 - S47Sholler, Giselle SaulnierFerguson, WilliamBergendahl, GenevieveBond, JeffreyNeville, KathleenEslin, DonBrown, ValerieRoberts, WilliamWada, RandyOesterheld, JavierMitchell, DeannaFoley, JessicaZage, PeterRawwas, JawharSencer, SusanKraveka, Jacqueline
- [36] Efficacy of naxitamab in patients with refractory/relapse (R/R) high-risk neuroblastoma (HR-NB) by bone/bone marrow (BM) evaluation, potential sites of residual disease.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Kushner, Brian H.Morgenstern, Daniel A.Nysom, KarstenBear, Melissa K.Tornoe, KarenLosic, NedjadMora, Jaume
- [37] Survival and palliative care decision making in high-risk neuroblastoma patients with refractory or relapsed disease: Experience from two paediatric oncology centres in the UKPEDIATRIC BLOOD & CANCER, 2007, 49 (04) : 568 - 568Ramanujachar, RamyaMarshall, LynleyDelany, JudithBrock, PenelopePritchard-Jones, Kathy
- [38] Safety and efficacy of naxitamab plus modified dosing of GM-CSF for patients with high-risk neuroblastoma (HR-NB) in first complete remission (CR) or with primary refractory diseaseJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Kushner, Brian H.Modak, ShakeelBasu, Ellen M.Cardenas, Fiorella IglesiasKramer, KimRoberts, Stephen S.Cheung, Nai-Kong V.
- [39] Reduction in curie score in neuroblastoma patients treated with naxitamab.JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Mora, JaumeChan, Godfrey Chi-FungMorgenstern, Daniel A.Amoroso, LoredanaNysom, KarstenFaber, JoergWingerter, ArthurBear, MelissaRubio-San-Simon, AlbaKushner, Brian H.Tornoe, KarenChristensen, Rene DePont
- [40] Naxitamab-Based Chemoimmunotherapy for Resistant High-Risk Neuroblastoma: Preliminary Results of Hits TreatmentPEDIATRIC BLOOD & CANCER, 2020, 67 : S32 - S32Mora, J.Castaneda, A.Flores, M.Gorostegui, M.Simao, M.Santa-Maria, V.Garraus, M.Chamizo, A.Lazaro, J. J.